Back to top
more

HCA Healthcare (HCA)

(Delayed Data from NYSE)

$318.91 USD

318.91
1,836,161

+1.93 (0.61%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $318.76 -0.15 (-0.05%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 7% (17 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acadia Healthcare (ACHC) Q3 Earnings Meet Estimates, Rise Y/Y

by Zacks Equity Research

Acadia Healthcare's (ACHC) Q3 results reflect higher revenues, driven by solid demand for its behavioral health services and higher admissions.

MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.

4 Hospital Stocks to Gain From Rebounding Patient Volumes

by Zacks Equity Research

Expanding patient volumes, use of telehealth services, cost-control measures and an aging demography are tailwinds to the hospital industry players like HCA, UHS, THC and ACHC.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Community Health's (CYH) Q3 Earnings Beat, Improve Y/Y

by Zacks Equity Research

Community Health's (CYH) third-quarter earnings gain from a solid revenue stream and lower expenses.

Molina Healthcare's (MOH) Q3 Earnings Beat Mark, Fall Y/Y

by Zacks Equity Research

Molina Healthcare (MOH) Q3 earnings gain from better revenues, partly offset by steep expenses.

Ensign Group (ENSG) Q3 Earnings Meet, '21 Earnings Guidance Up

by Zacks Equity Research

Ensign Group's (ENSG) third-quarter earnings gain from improved revenues, partly offset by steep expenses.

Teladoc Health (TDOC) Q3 Loss Narrower Than Expected, Down Y/Y

by Zacks Equity Research

Teladoc Health's (TDOC) third-quarter results indicate improved revenues owing to higher access fees and visit fees, partly offset by elevated costs.

LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up

by Zacks Equity Research

LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.

Encompass Health (EHC) Misses on Q3 Earnings, Cuts '21 EPS View

by Zacks Equity Research

Encompass Health's (EHC) third-quarter earnings miss estimates but improve year over year on the back of top-line growth resulting from a sound Inpatient Rehabilitation segment.

CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.

West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.

Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up

by Zacks Equity Research

Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.

Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View

by Zacks Equity Research

Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.

Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Universal Health (UHS) Q3 Earnings Miss Mark, Decline Y/Y

by Zacks Equity Research

Universal Health's (UHS) third-quarter results reflect high expenses, partly offset by better revenues.

Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.

Centene's (CNC) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Centene's (CNC) third-quarter results reflect improved revenues, better Medicare and Medicaid membership growth, partly offset by higher SG&A costs.

Srijita Guha headshot

4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes

by Srijita Guha

Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.

HCA Healthcare (HCA) Q3 Earnings Beat Estimates, Surge Y/Y

by Zacks Equity Research

HCA Healthcare's (HCA) Q3 earnings results reflect gains from patient volumes and better revenues.

HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

HCA (HCA) delivered earnings and revenue surprises of 11.46% and 4.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Should You Buy HCA Healthcare (HCA) Ahead of Earnings?

by Zacks Equity Research

HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.